Q-omics provides the consensus-scored GLCCI1 profile across patient tissues and cancer cell-line models. GLCCI1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GLCCI1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, GLCCI1 protein abundance shows 27,584 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BLCA, and LSCC as cancer lineages where GLCCI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLCCI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLCCI1 survival associations across molecular data types. GLCCI1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLCCI1 RNA expression–survival associations across cancer types. High GLCCI1 expression shows unfavorable associations in UVM, DLBC and ACC, but favorable associations in LUAD, HNSC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GLCCI1 RNA expression.
This table summarizes GLCCI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GLCCI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLCCI1 shows lower tumor expression in LUSC, THCA and LUAD and higher tumor expression in BLCA, KICH and UCEC. The BLCA box plot shows higher GLCCI1 RNA expression in tumor versus normal tissue (log2 FC = +1.521, t-test p < 0.001).
This table shows molecular features associated with GLCCI1 in patient tissues and cancer cell lines. In patient samples, GLCCI1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GLCCI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
